Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Papillon Therapeutics

PharmaDeviceNews Papillon Therapeutics

Automated cell therapy manufacturing could help Cellares and Papillon Therapeutics advance PPL-001 toward clinical development for Friedreich’s ataxia. Representative image.

Pharma & Biotech

Can Cellares automation move Papillon’s PPL-001 closer to a Friedreich’s ataxia trial?

by Pallavi Madhiraju
July 22, 2026
0 Comments

Cellares will automate PPL-001 manufacturing for Friedreich’s ataxia, but IND-enabling work and human evidence remain ahead.

Read More

Latest news and features

Forlong Biotechnology doses first patient in Australian Phase 1 trial of subcutaneous FL115
Natera’s Signatera Genome separates bladder cancer patients into 91%, 81% and 55% survival groups, but can MRD guide treatment?
Neurogene reports rapid MECP2 expression and new gene regulation data for NGN-401 in Rett syndrome
Dyno Therapeutics reports 152-fold brain transduction improvement and new immune-evasive AAV capsid data at ESGCT 2026
Rumi Therapeutics signs option agreement for IND-ready RTX-7340 PDE2 inhibitor in Fragile X syndrome
Powerful Medical secures CPT code 1139T for Queen of Hearts AI ECG after FDA authorisation
Kivo Health raises $10m Series A led by Allumia Ventures to expand AI-powered care for chronic lung disease
Alterome Therapeutics schedules first Phase 1 clinical data presentation for pan-KRAS inhibitor ALTA3263
Arrowhead Pharmaceuticals secures NHS funding recommendation for REDEMPLO in familial chylomicronaemia syndrome
Afimetoran Phase 2 trial delivers significant lupus improvement as Beeline Medicines eyes pivotal studies
Tafenoquine combinations show promising parasite clearance in immunocompromised patients with babesiosis
REYOBIQ brain cancer trial: Cerenome advances targeted radiotherapy ahead of Phase 2 plans

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

Generac revenue surges 16% as $4.5bn data center backlog strengthens growth outlook
Israel election deadlock leaves Netanyahu ahead but short of majority as Arab parties gain leverage
CrowdStrike expands NVIDIA alliance to protect autonomous AI agents at the chip level
Cyclone Arnab kills three in Andhra Pradesh as 180,000 evacuated and 79,000 acres of crops damaged
Cadence unveils Maestro AI models with 30% design-quality gains as chip engineering enters agentic era

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.